Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +210,975.57%
#2 Beta Finance Beta Finance +8,979.03%
#3 Tribe Tribe +73.83%
#4 Orochi Network Orochi Network +53.40%
#5 Chainbase Chainbase +40.85%
#6 BabyBoomToken BabyBoomToken +34.25%
#7 Block Street Block Street +31.59%
#8 Chrema Coin Chrema Coin +28.62%
#9 Freysa AI Freysa AI +26.78%
#10 B3 (Base) B3 (Base) +25.98%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Clasificación en acciones #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Precio por acción
$0.00244926
Capitalización bursátil
$51.67K
Cambio (1 día)
5.88%
Cambio (1 año)
110.15%
País
GB
Comercio Nuformix plc (NFX)

Categoría

Healthcare
Ratio P/B de Nuformix plc (NFX)
Ratio P/B al March 2026 TTM: 5.52
Según los informes financieros más recientes y el precio de las acciones de Nuformix plc, el ratio P/B actual (TTM) es 5.52. Al final de 2024, el ratio P/B era 0.64.
Historial del ratio P/B de Nuformix plc desde 2014 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2026 (TTM) 5.52 6.74%
2025 5.17 703.62%
2024 0.64 44.29%
2023 0.45 -63.79%
2022 1.23 -46.40%
2021 2.30 -42.90%
2020 4.02 28.15%
2019 3.14 93.67%
2018 1.62 -108.69%
2017 -18.66 -793.31%
2016 2.69 0.00%
2014 0.00 0.00%
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6573 2.51%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3842 15.68%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4551 -55.51%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.364 -20.92%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5504 -53.79%
AU